We have previously [16, 17] applied next-generation sequencing (NGS) assays on plasma DNA in a retrospective ALK + NSCLC cohort and quantified ctDNA levels by variant allele frequencies (VAFmean) of single nucleotide variants and t-MAD scores [18], which inform gross copy number changes across the genome. This evidence concerns the gene ALK and non-small cell lung carcinoma.